OraSure Technologies, Inc.
http://www.orasure.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From OraSure Technologies, Inc.
Emerging Modalities Stand Out In Recovering Korean Deal Market
While Korean biopharma companies’ out-licensing deals have remained lackluster in the past couple of years, activity around emerging modalities, led by ADCs, have been increasing in line with global trends.
Lucky No. 13? Artiva Goes Public, Rises In First Day Of Trading
Artiva grossed $167m by selling more shares than previously planned, but at a significantly lower price per share than it proposed earlier in the week, to fund its NK cell therapy programs.
Finance Watch: US Market May Warm To Go-Public Options As Summer Progresses
Public Company Edition: The IPO market in the US cooled in Q2, but a warm-up may come in Q3 alongside new SPAC merger opportunities; Artiva may be the next biopharma firm to go public. Also, IDEAYA and Recursion grossed $302.4m and $200m, respectively, in follow-on offerings.
BIO Notebook: FDA User Fees For AI Regulation, Partnering Strategy Evolves, And More
Insights from Day Two of the BIO International Convention in San Diego include the evolving pros and cons of partnering, user fees potentially supporting the FDA's AI ambitions, and J&J's view on dealmaking in 2024.
Company Information
- Industry
- Biotechnology
- Distributors
- Services
-
Medical Devices
-
Diagnostic Imaging Equipment & Supplies
- Molecular Imaging
-
Diagnostic Imaging Equipment & Supplies
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Therapeutic Drug Monitoring
- Urine-based Testing
- Other Names / Subsidiaries
-
- Corebiome
- Diversigen
- DNA Genotek
- Novosanis
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice